Heart failure with preserved ejection fraction (HFpEF) is a heart failure subtype defined by left ventricular ejection fraction of at least 50% with elevated filling pressures. It is associated with substantial morbidity, reduced quality of life, and increased mortality despite preserved ejection fraction. HFpEF is pathophysiologically distinct from reduced-EF heart failure and often linked to aging, obesity, hypertension, diabetes, and atrial fibrillation.
A study of over 600,000 patients reveals GLP-1 drugs may reduce addiction across multiple substances, with 50% fewer substance-related deaths and significant reductions in overdoses and hospitalizations. The drugs work by dampening dopamine signaling in brain reward centers. Researchers are exploring broader applications for these medications beyond diabetes and obesity treatment.
Oral semaglutide reduced heart failure events by 22% in Type 2 diabetes patients with existing heart failure in a trial of nearly 9,650 adults, with particular benefit in HFpEF cases.
Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.
UK and Brazil issue warnings about possible pancreatitis link to GLP-1 weight-loss drugs, while WADA monitors their use in Olympic athletes amid concerns about muscle loss and performance effects.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07599293 |
Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims Data |
ACTIVE_NOT_RECRUITING | |
| NCT07554638 |
Incretin Therapies in Obesity-related HFpEF |
NOT_YET_RECRUITING | PHASE4 |
| NCT07413198 |
BOOST: Blended Onsite and Offsite Structured Exercise Training and Coaching |
NOT_YET_RECRUITING | NA |
| NCT07401771 |
Exercise Cardiovascular Magnetic Resonance In Heart Failure With Preserved Ejection Fraction |
RECRUITING | |
| NCT07331220 |
Pulmonary Artery Denervation for Heart Failure With Preserved Left Ventricular Ejection Fraction |
NOT_YET_RECRUITING | NA |
| NCT07269717 |
A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction |
RECRUITING | PHASE2 |
| NCT07254455 |
CASTLE-HFpEF (Catheter Ablation for Atrial Fibrillation Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction) |
NOT_YET_RECRUITING | NA |
| NCT07214376 |
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease |
NOT_YET_RECRUITING | NA |
| NCT07202000 |
EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07123779 |
Study of HS235 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF) |
NOT_YET_RECRUITING | PHASE1 |
